HACKENSACK, N.J. - (Business Wire) Amorcyte, Inc. (Amorcyte)
announced today the completion of the phase I clinical trial of its
lead product, AMR-001 – an autologous stem cell product for the
treatment of damaged heart muscle following acute myocardial
infarction (AMI).
"All treatment patients in each dose cohort of the phase I trial
received intra-coronary artery infusion of a specified number of stem
cells. The number of stem cells infused was increased over the
previous cohort", said Dr. Thomas Moss, Amorcyte's Chief Medical
Officer.
"We are excited to have completed the phase I clinical trial of AMR-
001 in patients with acute myocardial infarction (AMI), or heart
attack, who have suffered significant damage to their heart muscle,"
stated Arshed A. Quyyumi, MD, FRCP, FACC, Professor of Medicine,
Cardiology, at Emory University School of Medicine and the trial's
principal investigator. "This trial has demonstrated proof of
principle for this type of cell-based therapy. We have shown that it
is possible to take progenitor stem cells harvested and extracted
from a patient's bone marrow shortly after a heart attack and deliver
these cells back into the patient's heart with the intent of
repairing the damaged heart muscle. We eagerly anticipate beginning a
phase II trial".
Amorcyte is a company led by experienced management and guided by the
outstanding expertise of a Scientific Advisory Board comprised of
Bernard J. Gersh, MB ChB, D.Phil, Professor of Medicine at Mayo
Clinic of Medicine and Consultant in Cardiovascular Diseases; Dean J.
Kereiakes, MD, Medical Director of the Heart Center of Greater
Cincinnati at Christ Hospital; Emerson C. Perin, MD, PhD, FACC,
Director, New Interventional Cardiovascular Technology, Texas Heart
Institute; Arshed A. Quyyumi, MD, FRCP, FACC, Professor of Medicine,
Cardiology, Emory University School of Medicine; Edmund Waller, MD,
PhD, FACP, Professor of Medicine at Emory Health Care Division of
Cardiology; Ned Waller, MD, Professor of Medicine, Hematology and
Stem Cell Biology, Emory University School of Medicine; James T.
Willerson, MD, President of the University of Texas Health Science
Center; and Ching Zhu, PhD, MBA, Partner, PA Early Stage Partners
formerly of Guidant Corp.
"We believe that with the guidance of our external advisors, we have
an unparalleled clinical trial strategy which, combined with our
approach to corporate development, provides an outstanding
opportunity for both clinical and commercial success," states Andrew
L. Pecora, MD, Amorcyte's Board Chairman. Results form pre-clinical
studies were reported at the 2007 American Society of Hematology
Meeting. The company anticipates reporting preliminary clinical
results later this year.
About Cardiovascular Disease
It is estimated that each year there are approximately 1.1 million
instances of acute myocardial infarctions, 12 million cases of
chronic ischemia and 5 million occurrences of congestive heart
failure in the United States. A significant percentage of these
patients may benefit from additional therapies to ameliorate the
symptoms of their disease. Therapies like those being developed by
Amorcyte are under active investigation to determine safety and
efficacy.
About Amorcyte, Inc.
Amorcyte is a privately funded biotechnology company developing cell
therapy products to treat cardiovascular disease, reimbursable on a
commercial scale for widespread clinical use. Amorcyte has partnered
with Progenitor Cell Therapy, a leading cell therapy contract service
provider for clinical, manufacturing and other services. For more
information, visit www.amorcyte.
This press release does not constitute an offer to sell, or a
solicitation of any offer to buy any securities of Amorcyte. In
addition, certain of the statements in this press release are forward-
looking statements relating to such matters as anticipated financial
performance, business prospects, technological developments, new
products, research and development activities and similar matters.
These statements involve known and unknown risks, uncertainties, and
other factors that may cause the company or its industry's actual
results, levels of activity, performance, or achievements to be
materially different from any future results, levels of activity,
performance, or achievements expressed or implied by such forward-
looking statements. In some cases, you can identify forward-looking
statements by terminology such
as "may," "intend," "will," "should," "expect," "plan," "anticipate,
"believe," "estimate," "predict," "potential" or "continue" or the
negative of such terms or other comparable terminology. Forward-
looking statements are only predictions. Actual events or results may
differ materially. Although the company believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee future results, levels of activity,
performance or achievements. Moreover, neither the company nor any
other person assumes responsibility for the accuracy and completeness
of such statements. The company is under no duty to update any of the
forward-looking statements after the date of this press release to
conform such statements to actual results.
Amorcyte, Inc.
Andrew L. Pecora, Chairman of the Board, (201) 996-5814
apecora@amorcyte.
http://www.earthtim
trial,335003.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
